Skip to main content
Clinical Trials/NCT04260750
NCT04260750
Completed
Not Applicable

ICBT for Depression - A Factorial Investigation of Kinds of Therapist Support and Self-/Expert-selected Content

Linkoeping University1 site in 1 country246 target enrollmentJanuary 13, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depressive Disorder, Major
Sponsor
Linkoeping University
Enrollment
246
Locations
1
Primary Endpoint
Change on Patient Health Questionnaire (PHQ-9)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study is a factorial randomized controlled trial investigating the efficacy of difference versions of internet-administered cognitive behavioral therapy.

Detailed Description

The study is a 2 x 2 design. The first factor thought to be of relevance for the efficacy is the whether the content is selected by the participants themselves or by a therapist. The second factor consists of two levels: regular, continuous weekly support from a therapist or guidance on demand by a health care team consisting of a physician, a nurse, a clinical psychologist, an IT-technician and the principal investigator of the study.

Registry
clinicaltrials.gov
Start Date
January 13, 2020
End Date
April 15, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Sponsor
Linkoeping University
Responsible Party
Principal Investigator
Principal Investigator

Gerhard Andersson

Professor

Linkoeping University

Eligibility Criteria

Inclusion Criteria

  • Current depressive symptoms equivalent to a score of at least 5 on Patient Health Questionnaire 9 and a minimum of 10 points on Becks Depression Inventory.
  • 18 years or older.
  • Adequate ability to understand and speak Swedish.
  • Access to the internet and a smartphone/computer.

Exclusion Criteria

  • Other ongoing psychological treatment or counselling.
  • Recent (within the past 3 months) changes in the dose of psychotropic medication.
  • Prior diagnosis of psychosis, bipolar disorder, or substance dependence.

Outcomes

Primary Outcomes

Change on Patient Health Questionnaire (PHQ-9)

Time Frame: Baseline, during week 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 of the intervention, post-intervention (after 11 weeks), 12 months after the end of intervention.

Measure of depressive symptoms. Possible range for the total sum: 0 to 27 (created by summing up the score from each item). Clinical cut-offs for mild, moderate, moderately severe and severe major depressive disorder are considered to be 5, 10, 15, and 20 points.

Change on Becks Depression Inventory-II (BDI-II)

Time Frame: Baseline, after the intervention (after 11 weeks), 12 months after the end of intervention.

Measure of depressive symptoms. Possible range for the total sum: 0 to 63 (created by summing up the score from each item). Clinical ranges for minimal, mild, moderate and severe major depressive disorder are considered to be 0-13, 13-19, 20-28, and 29-63 points.

Secondary Outcomes

  • Change on Generalised Anxiety Disorder 7-item scale (GAD-7)(Baseline, after the intervention (after 11 weeks), 12 months after the end of intervention.)
  • Change on Brunnsviken Brief Quality of Life Scale (BBQ)(Baseline, after the intervention (after 11 weeks), 12 months after the end of intervention.)
  • Change on Insomnia Severity Index (ISI)(Baseline, after the intervention (after 11 weeks), 12 months after the end of intervention.)

Study Sites (1)

Loading locations...

Similar Trials